Pathophysiology, clinical presentation, and treatment of psoriasis: a review
Importance Approximately 125 million people worldwide have psoriasis. Patients with
psoriasis experience substantial morbidity and increased rates of inflammatory arthritis …
psoriasis experience substantial morbidity and increased rates of inflammatory arthritis …
Challenges and future trends in the treatment of psoriasis
HJ Lee, M Kim - International Journal of Molecular Sciences, 2023 - mdpi.com
Psoriasis is a chronic inflammatory skin disorder, and current treatments include topical
therapies, phototherapy, systemic immune modulators, and biologics, aiming to alleviate …
therapies, phototherapy, systemic immune modulators, and biologics, aiming to alleviate …
Psoriasis
Psoriasis is a common, chronic papulosquamous skin disease occurring worldwide,
presenting at any age, and leading to a substantial burden for individuals and society. It is …
presenting at any age, and leading to a substantial burden for individuals and society. It is …
[HTML][HTML] Phase 3 trials of tapinarof cream for plaque psoriasis
MG Lebwohl, L Stein Gold, B Strober… - … England Journal of …, 2021 - Mass Medical Soc
Background Tapinarof cream is a topical aryl hydrocarbon receptor–modulating agent under
investigation for the treatment of psoriasis. Tapinarof modulates the expression of interleukin …
investigation for the treatment of psoriasis. Tapinarof modulates the expression of interleukin …
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
Objectives Janus kinase inhibitors (JAKi) have been approved for use in various immune-
mediated inflammatory diseases. With five agents licensed, it was timely to summarise the …
mediated inflammatory diseases. With five agents licensed, it was timely to summarise the …
Classification of human chronic inflammatory skin disease based on single-cell immune profiling
Inflammatory conditions represent the largest class of chronic skin disease, but the
molecular dysregulation underlying many individual cases remains unclear. Single-cell RNA …
molecular dysregulation underlying many individual cases remains unclear. Single-cell RNA …
[HTML][HTML] Focus: skin: current developments in the immunology of psoriasis
F Grän, A Kerstan, E Serfling, M Goebeler… - The Yale journal of …, 2020 - ncbi.nlm.nih.gov
Psoriasis is a frequent inflammatory skin disease. Fundamental research on the
pathogenesis of psoriasis has substantially increased our understanding of skin …
pathogenesis of psoriasis has substantially increased our understanding of skin …
Treatment guidelines in psoriatic arthritis
Psoriatic arthritis (PsA) is a complex inflammatory musculoskeletal and skin disease. The
treatment of PsA has changed substantially over the past 10 years. Clinical practice …
treatment of PsA has changed substantially over the past 10 years. Clinical practice …
[HTML][HTML] Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor–modulating agent
R Bissonnette, LS Gold, DS Rubenstein… - Journal of the American …, 2021 - Elsevier
Tapinarof, a novel, first-in-class small-molecule topical therapeutic aryl hydrocarbon
receptor (AhR) modulating agent (TAMA), is in clinical development for the treatment of …
receptor (AhR) modulating agent (TAMA), is in clinical development for the treatment of …
Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review
Psoriasis is a common inflammatory skin disease with multiple comorbidities, including
psoriatic arthritis and coronary artery disease, that can severely impact an individual's …
psoriatic arthritis and coronary artery disease, that can severely impact an individual's …